212 related articles for article (PubMed ID: 23989944)
1. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
Reyes D; Salazar L; Espinoza E; Pereda C; Castellón E; Valdevenito R; Huidobro C; Inés Becker M; Lladser A; López MN; Salazar-Onfray F
Br J Cancer; 2013 Sep; 109(6):1488-97. PubMed ID: 23989944
[TBL] [Abstract][Full Text] [Related]
2. TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
Salazar-Onfray F; Pereda C; Reyes D; López MN
Biol Res; 2013; 46(4):431-40. PubMed ID: 24510145
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F
Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818
[TBL] [Abstract][Full Text] [Related]
5. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
[TBL] [Abstract][Full Text] [Related]
6. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA
J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371
[TBL] [Abstract][Full Text] [Related]
8. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C; Segal G; Salazar L; Pereda C; Falcón C; Tempio F; Aguilera R; González R; Pérez C; Tittarelli A; Catalán D; Nervi B; Larrondo M; Salazar-Onfray F; López MN
Cancer Immunol Immunother; 2013 Apr; 62(4):761-72. PubMed ID: 23242374
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
Tittarelli A; González FE; Pereda C; Mora G; Muñoz L; Saffie C; García T; Díaz D; Falcón C; Hermoso M; López MN; Salazar-Onfray F
Cancer Immunol Immunother; 2012 Nov; 61(11):2067-77. PubMed ID: 22552381
[TBL] [Abstract][Full Text] [Related]
10. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
11. An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells.
Tomasicchio M; Semple L; Esmail A; Meldau R; Randall P; Pooran A; Davids M; Cairncross L; Anderson D; Downs J; Malherbe F; Novitzky N; Panieri E; Oelofse S; Londt R; Naiker T; Dheda K
Cancer Immunol Immunother; 2019 Jan; 68(1):71-83. PubMed ID: 30283982
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
13. B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer.
Lian T; Hao X; Li J; Wang H; Li C
Med Oncol; 2020 Nov; 37(11):107. PubMed ID: 33136217
[TBL] [Abstract][Full Text] [Related]
14. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
Kongsted P; Borch TH; Ellebaek E; Iversen TZ; Andersen R; Met Ö; Hansen M; Lindberg H; Sengeløv L; Svane IM
Cytotherapy; 2017 Apr; 19(4):500-513. PubMed ID: 28215654
[TBL] [Abstract][Full Text] [Related]
16. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells.
González FE; Ortiz C; Reyes M; Dutzan N; Patel V; Pereda C; Gleisner MA; López MN; Gutkind JS; Salazar-Onfray F
Immunology; 2014 Jul; 142(3):396-405. PubMed ID: 24673602
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions.
Falcón-Beas C; Tittarelli A; Mora-Bau G; Tempio F; Pérez C; Hevia D; Behrens C; Flores I; Falcón-Beas F; Garrido P; Ascui G; Pereda C; González FE; Salazar-Onfray F; López MN
Immunobiology; 2019 Sep; 224(5):697-705. PubMed ID: 31221438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
